Russell Investments Group Ltd. increased its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 2.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 50,545 shares of the biopharmaceutical company’s stock after purchasing an additional 1,251 shares during the period. Russell Investments Group Ltd.’s holdings in Madrigal Pharmaceuticals were worth $25,473,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of the company. Jupiter Topco LLC acquired a new position in shares of Madrigal Pharmaceuticals in the second quarter valued at $1,039,650,000. Paulson & CO. Inc. bought a new position in Madrigal Pharmaceuticals in the second quarter worth $719,524,000. BlackRock Inc. acquired a new stake in Madrigal Pharmaceuticals during the second quarter worth $644,753,000. Janus Henderson Group PLC boosted its stake in Madrigal Pharmaceuticals by 27.4% during the first quarter. Janus Henderson Group PLC now owns 2,018,647 shares of the biopharmaceutical company’s stock worth $1,051,727,000 after buying an additional 433,804 shares in the last quarter. Finally, William Blair Investment Management LLC bought a new stake in Madrigal Pharmaceuticals in the 2nd quarter valued at $174,038,000. 98.50% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other news, General Counsel Shannon T. Kelley sold 1,077 shares of the business’s stock in a transaction on Friday, November 6th. The shares were sold at an average price of $400.00, for a total value of $430,800.00. Following the sale, the general counsel owned 10,397 shares in the company, valued at approximately $4,158,800. The trade was a 9.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO William Sibold sold 6,362 shares of the business’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $535.59, for a total transaction of $3,407,423.58. Following the completion of the sale, the chief executive officer owned 202,967 shares in the company, valued at $108,707,095.53. This represents a 3.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 12,660 shares of company stock worth $6,670,042 over the last three months. 17.60% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
MDGL has been the subject of a number of recent research reports. Canaccord Genuity Group increased their price objective on shares of Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. HC Wainwright reaffirmed a “buy” rating on shares of Madrigal Pharmaceuticals in a report on Thursday, November 12th. UBS Group reiterated a “buy” rating and set a $735.00 target price on shares of Madrigal Pharmaceuticals in a research report on Wednesday, October 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research note on Thursday, October 15th. Finally, Wolfe Research raised shares of Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 price target for the company in a research report on Tuesday, August 4th. Fourteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $706.87.
Check Out Our Latest Stock Analysis on MDGL
Madrigal Pharmaceuticals Trading Down 0.5%
Shares of MDGL opened at $421.99 on Wednesday. The company has a current ratio of 3.05, a quick ratio of 2.78 and a debt-to-equity ratio of 0.54. The stock has a market cap of $9.80 billion, a PE ratio of -70.57 and a beta of -0.98. Madrigal Pharmaceuticals, Inc. has a 1 year low of $353.54 and a 1 year high of $615.00. The stock has a 50 day simple moving average of $471.14 and a 200-day simple moving average of $495.06.
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 EPS for the quarter, beating the consensus estimate of ($1.09) by $2.92. The business had revenue of $431.27 million for the quarter, compared to analyst estimates of $404.17 million. Madrigal Pharmaceuticals had a negative return on equity of 27.08% and a negative net margin of 10.89%. During the same quarter in the previous year, the firm earned ($5.08) EPS. On average, sell-side analysts predict that Madrigal Pharmaceuticals, Inc. will post -2.08 EPS for the current fiscal year.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania. Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.
See Also
- Five stocks we like better than Madrigal Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding MDGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report).
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
